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The aim of this study was to analyse the correlation 
between HPV16 E6 variants and the physical status of 
viral genome (integrated, mixed, episomal) among pa-
tients with cervical cancer (n=40) and low-grade squa-
mous intraepithelial lesions – LSIL (n=40). The study 
was performed on 80 HPV16 positive samples. HPV16 
E6 variants were identified using PCR and DNA sequenc-
ing. Nucleotide sequences of E6 were compared with 
the prototype sequence (EUR-350T). The physical state 
of HPV DNA was determined as the ratio of E2/E6 copy 
number per cell. Twelve different intratypic variants 
were identified as belonging to European (in 77 samples) 
and North-American 1 (in 3 samples) sublineages. The 
most prevalent non-synonymous variant was EUR-350G, 
which occurred with similar frequency in cervical cancer 
and LSIL. The frequencies of additional mutations in vari-
ants with EUR-350T or EUR-350G sequences differed sig-
nificantly. For the first time, missense mutations G122A, 
C153T and G188A were discovered in EUR-350G variant. 
The integrated viral genome was predominant in women 
with cervical cancer. The EUR-350T prototype and EUR-
350G without additional mutations variants were preva-
lent in cervical cancer samples with the HPV16 character-
ized by integrated DNA. In summary, European variants 
of HPV16 E6 dominated in both cancer and LSIL group. 
The presence of EUR-350G favoured the occurrence of 
additional nucleotide changes. We showed that nucleo-
tide changes occur significantly more often in the mixed 
form of viral DNA and in LSIL group and that the vari-
ants without additional mutations may promote integra-
tion of HPV16 genome.
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INTRODUCTION
Human papillomavirus type 16 (HPV16) has been 
classified into Alphapapillomavirus-9 species belonging 
to Papillomaviridae family. It is the most common type 
detected in early and malignant cervical lesions in the 
world as well as in some HPV-related cancers of the 
vulva, vagina, penis, anus, and oropharynx (Crow, 2012; 
Garbuglia, 2014; Bruni et al., 2015).
Persistent infection with oncogenic human papilloma-
virus genotypes is essential, although not sufficient, to 
cause invasive cervical cancer and cervical intraepithelial 
neoplasia as its precursor (Walboomers et al., 1999; Mu-
noz et al., 2003).
The distribution of HPV genotypes in various pop-
ulations and areas is different and the epidemiological 
studies suggest that certain HPV16 E6 variants could in-
fluence the persistence of infection, progression to pre-
cancer and cancer development (Londesborough et al., 
1996). A distinct HPV type is confirmed when the DNA 
sequence of the L1 ORF of the cloned viral genome dif-
fers from that of any other characterised type by at least 
10% but isolates of the same HPV type are named as 
subtypes when the nucleotide sequences of the L1 ORF 
differ by less than 10% (de Villiers et al., 2004; Bernard 
et al., 2010). Cornet and coworkers (2012) proposed to 
define major variant lineages based on approximately 
1.0% difference between full genomes of the same HPV 
type while variant sublineages by 0.5–0.9% differences. 
Variants of E6 HPV16 were divided into four distinct 
phylogenetic branches, the distribution of which varies 
geographically: lineage A – European-Asian, including 
the sublineages European (EUR) and Asian (As); lineage 
B – African 1 (Afr1) with Afr1a and Afr1b sublineages; 
lineage C – African 2 (Afr2) including Afr2a and Afr2b 
sublineages and lineage D – Asian American/North 
American including Asian American 1, Asian American 2 
and North American 1 sublineages (Burk, 2013, Cornet 
et al., 2012).
Lee and coworkers (2008) proposed that nucleotide 
polymorphism within the E6 sequence of HPV16, rather 
than in other ORFs, influences the progression of cervi-
cal malignancy, and that additional factors are likely to 
play a significant role as well.
Integration of viral DNA into host cell genome is a 
frequent event in carcinogenesis. The HPV genome inte-
gration usually disrupts E2 gene, leading to overexpres-
sion of E6 and E7 oncogenes.
The aim of the present study was to identify HPV 16 
E6 variants and to analyse the physical status of HPV16 
genome (integrated and/or episomal form of viral DNA) 
among patients with cervical cancer in comparison to 
women with low-grade squamous intraepithelial lesions 
(LSIL).
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MATERIALS AND METHODS
Specimens and DNA extraction. The study was 
performed on eighty HPV16 positive cervical cytobrush 
samples confirmed by the INNO-LiPA HPV genotyp-
ing assay (Innogenetics). All HPV isolates included in 
the present study came from the collection of samples 
obtained from women (aged 22–90 years, mean 42±15) 
with invasive cervical carcinoma (n=40) and low-grade 
squamous intraepithelial lesions – LSIL (n=40). The 
LSIL group was dominated by younger women (up to 
40 years of age) and women over the age of 50 were 
predominant in the cervical cancer group (p<0.001). All 
samples were taken after cytological examination, but 
before any treatment. All cancer patients were treated 
at the Maria Skłodowska-Curie Memorial Cancer Cen-
tre and Institute of Oncology, Cracow Branch, Poland. 
The study was approved by the Ethics Committee of the 
Jagiellonian University.
DNA was isolated from cervical smears and purified 
using Genomic DNA Prep Plus kit (A&A Biotechnolo-
gy, Poland) according to the manufacturer’s instructions.
HPV 16 E6 variants identification. Determination 
of HPV16 E6 variants was performed using PCR with 
type-specific E6 primers according to Zuna and cowork-
ers (2009) and followed by DNA sequencing.
The final PCR reaction contained 50 ng of the isolat-
ed DNA, 1x PCR Buffer II (Applied Biosystems, USA), 
2 mM MgCl2, 200 µM dNTPs, 2 µM each primer and 1 
U AmpliTaq Gold DNA polymerase (Applied Biosyste-
ms, USA). The specific primers, flanking the encoding 
E6 open reading frame (nt 83 – 559) comprised: 5’ – 
TGA ACC GAA ACC GGT TAG TA – 3’ and 5’ – 
CAT GCA ATG TAG GTG TAT CTC C – 3’. The 
PCR conditions were as follows: polymerase activation 
3 min at 94ºC, 40 cycles of denaturation at 94ºC for 1 
min, annealing at 55ºC for 1min, and extension at 72ºC 
for 2 min, and a final elongation at 72ºC for 7 min. For 
every reaction, positive control using DNA extracted 
from SiHa cell line, as well as a negative control without 
template DNA (H2O), were included.
The amplified DNA fragments were tested by electro-
phoresis in 2% agarose gel with ethidium bromide. The 
PCR products were sequenced by Genomed (Poland).
 The ExoSAP-IT clean up kit (USB, USA) was used 
to purify these products and DNA sequences were ob-
tained with an ABI 3730xl DNA Analyzer or 3130xl 
Genetic Analyzer (Applied Biosystems, USA) using the 
same primers as those used for PCR and BigDye™ Ter-
minator V3.1 Cycle Sequencing Kits (Applied Biosyste-
ms, USA). The same forward and reverse primers were 
used separately in cycle sequencing in order to sequence 
both sense and antisense strands.
The obtained HPV16 E6 sequences were aligned 
with those of European prototype of HPV16 sequence 
(GenBank accession numbers: K02718, NC_001526), 
and compared with those of known HPV types available 
through the GenBank database (NCBI, National Insti-
tute of Health, Bethesda, MD, USA), using the BLAST 
2.0 and ChromasPro 1.5 software.
HPV16 physical status determination. The method 
of the viral physical state assessment as a ratio of E2 to 
E6 copy numbers per cell was described in our previ-
ous paper (Szostek et al. 2015). Amplification was per-
formed using the ABI Prism 7500 Fast Real-Time PCR 
Systems for HPV16 E6 and E2 sequences. The quan-
tity of E2 and E6 genes was detected simultaneously by 
multiplex quantitative PCR. The load of E2 and E6 was 
determined using a copy number normalized per cell. 
The number of cells was assessed by qPCR targeting the 
RNase P open reading frame. The E2/E6 ratios were 
calculated to determine the pure episomal (E2/E6≥1.0), 
the mix of integrated and episomal (0.99>E2/E6>0.05) 
and the integrated (E2/E6≤0.05) forms present in a sin-
gle sample.
Statistical analysis. The statistical analysis was per-
formed using the STATA 10.0 software package. De-
scriptive statistics were used to determine mean value of 
continuous variables and standard errors of means. Cor-
relations between Ct levels were analysed by correlation 
matrix in which R coefficients and p values were calcu-
lated. The distribution of HPV16 variants in the inves-
tigated groups and in different physical status forms of 
viral DNA was described using descriptive statistics and 
non-parametric Mann–Whitney U test for the number of 
nucleotide changes in the analysed sequences. Dichoto-
mous variables were analysed using the chi-square test. 
A p-value less than 0.05 was considered significant. A 
multivariate logistic regression analysis was used for as-
sessing the relationship between clinical diagnosis and 
the occurrence of nucleotide changes.
RESULTS
HPV16 E6 variants detection
Nucleotide sequences of the complete E6 ORF from 
80 patients were compared with the HPV16 E6 proto-
type sequence (GenBank KO2718). Table 1 shows vari-
ant analysis for the E6 gene. A total of 12 different in-
tratypic variants were identified and were classified into 
two different lineages (A and D), including European 
(EUR) and the North-American 1 (NA1) sublineages.
Among the sequences belonging to the European 
sublineage, 26 out of 77 (34%) were identical with the 
prototype sequence (EUR-350T). Moreover, there were 
only 3 samples with the EUR-350T sequence with an 
additional single nucleotide changes, at position T137G 
(n=2), resulting in amino acid change (L12V), and at 
T109C without amino acid change (silent mutation), in 
one case. EUR-350T was present in 32.5% (13/40) of 
cervical cancer samples and in 16/40 (40%) of the LSIL 
group, but the differences were not statistically signifi-
cant. The EUR-350G variants were the most frequently 
detected isolates in our population and represented 60% 
(48/80) of total HPV16 samples, with similar frequency 
in cervical cancer and LSIL groups. The NA1 subline-
age was detected in 4% (3/80) of samples, only in the 
cervical cancer group. Distribution of HPV16 E6 vari-
ants according to different sublineages in LSIL and car-
cinoma groups was not statistically different (Pearson’s 
chi-squared, p=0.19).
Sequence analysis of 80 studied samples showed 
substitutions in 9 nucleotides located between posi-
tions 122 and 350 (G122A, T137G, G145T, C153T, 
G176A, G188A, T295G, C335T, T350G) leading 
to the amino acid change (E7K, L12V,Q14H, T17I, 
D25N, E29K, D64E, H78Y, L83V) while other nu-
cleotide substitutions (T109C, C256T, T286A, A289G) 
were silent. Moreover, for the first time, unknown 
missense mutations G122A, C153T and G188A were 
recorded along with EUR-350G (Table 1). Only in 
two cases, the amino acid changes (Q14H and T17I) 
were non-conservative, while other changes were con-
servative. The most prevalent non-synonymous variant 
was L83V (T350G). It was found in 64% (51/80) of 
samples in both the European and NA1 sublineages, 
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either alone (47%, 24/51) or along with other nucleo-
tide changes (53%, 27/51). The prevalence of T350G 
was similar in cervical cancer and LSIL groups and 
amounted to 67.5% and 60%, respectively (Pearson’s 
chi-squared, p=0.48). Missense mutations in nucleo-
tides other than EUR-350G were detected in individ-
ual samples. Among the synonymous variants T109C 
dominated (16%, 13/80).
In samples of the European lineage, frequencies of 
additional mutations (synonymous and non-synonymous) 
in variants with EUR-350T or EUR-350G sequences dif-
fered significantly and occurred in 10% (3/29) and 50% 
(24/48) of samples, respectively (Pearson’s chi-squared, 
p=0.0004). Furthermore, additional mutations (excluding 
T350G) in these samples were observed more often in 
LSIL than in cervical cancer, in 47.5% and 21.6% re-
spectively (Pearson’s chi-squared, p=0.02) 
(Fig. 1). The number of all mutations, in-
cluding three missense mutations and two 
silent ones, calculated per sample was high-
est in the NA1 sublineage variant. In Euro-
pean variants, only one or two nucleotide 
changes were observed. The average number 
of mutations per sample was not statistically 
significant when comparing cancer and LSIL 
patients (Mann–Whitney U test, p=0.29). 
However, silent mutations were pointed out 
in the LSIL group significantly more often 
(Pearson’s chi-squared, p=0.003) as shown in 
Fig. 1. A multivariate logistic regression anal-
ysis showed that the presence of synonymous 
mutations was correlated with a six-fold (OR 
6.1; 95% CI 1.55 – 24.00; p=0.003) increase 
in the probability of the occurrence of the 
LSIL diagnosis. The occurrence of mutation 
for the entire group (N=80) did not correlate 
with women’s age (Mann–Whitney U test, 
p=0.84).
Table 1. HPV16 E6 variants and their lineage identified in 80 patients with cervical cancer and low–grade squamous intraepithelial 
lesions. 
Capital letters indicate variants with an amino acid change, while small letters indicate silent mutation; at the bottom of the table amino 
acid changes are marked; N* – total cases; LSIL – low-grade squamous intraepithelial lesions; ICC – invasive cervical cancer; AA – amino 
acid.
Nucleotide 
position 109 122 137 145 153 176 188 256 286 289 295 335 350
HPV16  
prototype T G T G C G G C T A T C T
Line-
age
Subline-
age Class/subclass N*=80 LSIL=40 ICC=40
A EUR–p EUR–350T – – – – – – – – – – – – – 26 13 13
EUR–350T/137G – – G – – – – – – – – – – 2 2 0
EUR–350T/109C c – – – – – – – – – – – – 1 1 0
EUR–350G EUR–350G – – – – – – – – – – – – G 24 8 16
EUR–350G/109C c – – – – – – – – – – – G 12 9 3
EUR–350G/122A – A – – – – – – – – – – G 2 2 0
EUR–350G/153T – – – – T – – – – – – – G 1 1 0
EUR–350G/176A – – – – – A – – – – – – G 1 0 1
EUR–350G/188A – – – – – – A – – – – – G 1 0 1
EUR–350G/256T – – – – – – – t – – – – G 4 4 0
EUR–350G/295G – – – – – – – – – – G – G 3 0 3
D NA1 – – – T – – – – a g – T G 3 0 3
Codon position 7 12 14 17 25 29 64 78 83
Reference AA E L Q T D E D H L
Mutated AA K V H I N K E Y V
Figure 1. Distribution of additional nucleotide changes (without T350G) in 
the European variants of samples with LSIL and cervical carcinoma taking 
into account synonymous and non-synonymous mutations.
The differences of mutations number between groups were significant 
(Pearson’s chi-squared, p=0.02).
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Detection of HPV16 physical status
The integrated HPV16 DNA was identified in 24 
(30%), mixed form (episomal and integrated in the 
same sample) in 45 (56.3%) and episomal form in 11 
(13.7%) samples. Physical status of HPV16 genome re-
lated to the studied groups (cervical cancer and LSIL) 
was significant (Fig. 2). The integrated and mixed forms 
of HPV16 DNA were statistically more often found in 
cervical cancer than in the LSIL group (48.7% vs 37.5% 
respectively; V-chi-squared test, p=0.004). Among the 
isolates containing the episomal form of HPV16 DNA, 
91% were defined as LSIL.
In women with LSIL, the episomal form of HPV16 
DNA was present in 25%, while the mixed form in 72% 
of cases. Only one material (2.5%) was demonstrated to 
have integrated HPV16 genome. The integrated viral ge-
nome was predominant in women with cervical cancer 
(23/40, 57.5%). The mixed form of HPV16 DNA was 
found in 40% of women with cancer, whereas the episo-
mal form was shown only in one patient.
Association of HPV16 E6 polymorphisms with viral 
genome physical state
In NA1 variant mixed form of HPV16 DNA was 
identified. Figure 3 shows occurrence of EUR-350T 
and EUR-350G variants in relation to the physical sta-
tus of HPV16 DNA. The EUR-350G variant dominated 
in mixed form while EUR-350T was slightly 
more often present as the integrated form. 
These differences were statistically significant 
(Pearson’s chi-squared test, df=2, p<0.0001).
As regards the European variant, all mu-
tations (non-synonymous as well as syn-
onymous) were most frequently detected in 
mixed form compared to integrated form, 
68.63% (35/51) and 25.49% (13/51), re-
spectively. Only 3 samples with episomal 
forms of HPV16 genome contained the nu-
cleotide changes (Pearson’s chi-squared test, 
p=0.0007). In multivariate analysis, the distri-
bution of the different variants depending on 
the form of the HPV16 genome and cyto-
logical diagnosis showed that in the samples 
of cervical cancer with the integrated form, 
EUR-350T prototype and EUR-350G with-
out additional mutations were the most fre-
quently observed. These results were statisti-
cally significant and amounted to, respective-
ly: 43% (10/23); Pearson’s chi-squared 13.1 
(df=2), p=0.001 and 47% (11/23); Pearson’s chi-squared 
10.9 (df=2), p=0.004. For the other variants, there was 
no such relationship. Figure 4 demonstrates the aver-
age number of nucleotide changes present in materials 
assigned to particular groups depending on the form of 
HPV16 genome. The percentage of synonymous and 
non-synonymous mutations in three forms of HPV16 
genome was shown in Fig. 5.
Among samples with the episomal form, isolates in 
which the prototype sequence EUR-350T was detected 
were predominant (72.7%, 8/11), while non-synonymous 
mutations usually were observed in the mixed and in-
tegrated forms, 34/42 and 13/24, respectively. These 
differences were statistically significant (Pearson’s chi-
squared test, p=0.002).
DISCUSSION
HPV16 is the most commonly encountered high risk 
type of HPV in Polish women with cervical cancer. Di-
versity of the HPV16 E6 sequence was investigated in 
women from southern Poland. For the first time, in 
the present study, we also analysed the relationship be-
tween the polymorphism of HPV16 E6 gene and the 
viral genomic physical status in this patient group. It is 
widely accepted that the distribution of HPV variants 
is related to geographical or population eth-
nicity distribution (Xi et al., 2006; de Araujo 
Souza et al., 2009; Cornet et al., 2013a). In 
the present study, of 80 HPV16 positive 
women, European lineage variants (both 
prototype and related variant), were domi-
nant (96%) in both LSIL and cervical cancer 
group. In 3 (4%) cases, only in the cervical 
cancer group, North American sublineage 
was detected. Similar results were obtained 
in Slovenian patients with cervical cancer, 
where mainly European genomic variations 
of HPV16 were found and only 2/40 (5%) 
of the cases were associated with non-Euro-
pean HPV16 genomic variants – the Asian-
American and African 2 branches (Vrtačnik 
Bokal et al., 2010). Several studies showed 
that non-European HPV16 genomic variants 
(lineage B, C, D) are associated with stronger 
oncogenic potential than the European line-
Figure 2. Physical state of HPV16 in relation to the studied groups (n=40 
LSIL; n=40 cervical cancer).
The differences between groups were significant (Pearson’s chi-squared 26.9 
(df=2), p<0.0001).
Figure 3. Physical state of HPV16 genome (episomal, mixed, integrated 
forms) in EUR-350T and EUR-350G variants.
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age A (Hildescheim et al., 2001; Xi et al., 2007; Sichero et 
al., 2007; Schiffman et al., 2010; Freitas et al., 2014; Or-
tiz-Ortiz et al., 2015). Moreover, the Asian American//
North American (AA/NA ) variants were linked to high-
er capacity of in vitro transformation of human keratino-
cytes (Sichero et al., 2012).
On the other hand, studies performed in Sweden, 
Germany and the Netherlands failed to confirm such 
relationship between European and non-European line-
ages (Zehbe et al., 1998; Nindl et al., 1999; van Duin et 
al., 2000). However, almost 20 years ago, Yamada and 
coworkers (1997) analysed HPV16 sequence variation in 
a worldwide collection of cervical cancer specimens and 
showed that European lineage variants predominated in 
Europe and North America and a single North-Ameri-
can 1 variant was detected only in Argentina. While in 
recent research by Cornet and coworkers (2013a), it was 
suggested that there is an overrepresentation of AA/NA 
variants in cervical cancer cases in South/Central Ameri-
ca and shown that in Europe these variants are the most 
prevalent non-European variants (9/281, 3%). Also, 
both Burroni and coworkers (2013) 
in Italian women with LSIL and 
Gudleviciene and coworkers (2015) 
in Lithuanian women with cervical 
cancer revealed a single case of the 
North-American 1 variant, which is 
similar to our findings in the popu-
lation of women from the south of 
Poland.
The most common European 
polymorphism in E6 gene is a nu-
cleotide substitution at position 350 
(350G instead of 350T) that leads to 
a protein change in codon 83, leucine 
to valine (L83V). Notably, the same 
E-350G nucleotide variation is also 
a characteristic finding in all Asian-
American and North-American se-
quences (Zuna et al., 2009). In some 
previous studies in Danish, Swed-
ish and French populations, it was 
shown that this substitution is associ-
ated with an increased risk of cervical 
cancer (Andersson et al., 2000; Ze-
hbe et al., 2001; Grodzki et al., 2006). 
However, the association was not 
consistently observed in other stud-
ies (Cornet et al., 2013b; Freitas et al., 
2014). In our study, the EUR-350G pattern occurred at 
a similar rate, 67.5% in cervical cancers and 60% in low 
grade lesions and these differences were not statistically 
significant. Similar results in women with cervical can-
cer were observed in Slovenia (62.5%) (Vrtačnik Bokal 
et al., 2010) but a lower frequency (49%) of EUR 350G 
was reported across Europe in a recent meta-analysis 
(Tornesello et al., 2011). In our research the incidence 
of EUR-350G variant in the LSIL group was similar to 
the results of studies in Greece (64%) and in Italy (65%) 
but higher than in England (41%) (Tsakogiannis et al., 
2013; Burroni et al., 2013; Marongiu et al., 2014). In a 
recent study, the International Agency for Research on 
Cancer (IARC) HPV Variant Study Group revealed, by 
examining 1121 HPV16 positive cervical cancer cases 
and 400 HPV16 positive controls worldwide, that E-
350G is associated with an increased risk of developing 
cervical cancer in South and Central America but not in 
Europe nor Central Asia (Cornet et al., 2013a). Further-
more, EUR-350T infections were more likely to persist 
and progress to CIN3 than in case of EUR-350G 
in Denmark (Gheit et al., 2011). Also Cornet and 
coworkers (2013b) demonstrated an approxi-
mately twofold risk of HPV16 persistence in the 
presence of EUR-350T. European variants with 
the polymorphism in EUR-350T were revealed to 
persist more often than those containing EUR-
350G (OR=1.6, 95% CI=0.8-3.4).
In the previously conducted studies (Yamada 
et. al., 1997; Vrtačnik Bokal et al., 2010) additional 
nucleotide changes (T137G, G176A, T295G) oc-
curring in EUR-350G were identified only in in-
dividual cases similarly as in our study. The fre-
quencies of additional mutations (synonymous 
and non-synonymous) in EUR-350G variants 
were significantly higher than in EUR-350T in the 
present examination. These findings inspired us to 
try to assess the correlation between the presence 
of these additional mutations and clinical diagno-
sis and the physical status of HPV16 DNA. Addi-
tional mutations excluding T350G were observed 
Figure 4. The average number of all nucleotide changes in European variants E6 se-
quence depending on the HPV16 physical status (episomal, mixed, integrated forms).
Figure 5. Distribution of synonymous and non-synonymous mutations 
in European variants of HPV16 E6 sequence depending on the form of 
viral genome.
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in our samples more often in LSIL than in cervical can-
cer. Taking into consideration the relationship between 
the total number of nucleotide changes and the physical 
state of HPV16, we most frequently observed mutations 
in the mixed form of viral genome, while non-synony-
mous mutations were predominantly found in mixed and 
integrated states.
In our study, analysis of HPV16 E6 sequences showed 
three new (not found in the BLAST program) missense 
mutations associated with T350G in the LSIL (C153T, 
G122A) and cancer (G188A) group (Table 1). It seems 
that there is a large variability in HPV viruses circulating 
in the population affecting women with a low grade of 
cervical lesions, while in women with cancer, this vari-
ability is smaller. In the previous study we confirmed 
that together with the progression of changes in the di-
rection of tumorigenesis, in women with multiple geno-
type HPV infection, there is a natural selection leading 
to infection with one genotype and it is usually HPV16 
(Szostek et al., 2008a). Perhaps an analogical selection 
takes place also in case of mutated HPV16 strains along 
with the persistent infection and development of cancer.
Integration of the HPV genome in the host cell 
DNA represents a key step in the progression of cer-
vical lesions, as it allows the continuous overexpression 
of E6 and E7 oncoproteins and its transforming activi-
ties via their interaction with p53 and pRB, respectively 
(zur Housen, 2002). In the present study, the integrated 
HPV16 form was significantly more frequently detected 
in cervical cancer than in LSIL (Pearson’s chi-squared 
26.9 (df=2), p<0.0001). These results are consistent with 
other authors (Han et al., 2015; Shukla et al., 2014). In 
our previous study, the increase of frequency of the in-
tegrated HPV16 DNA with progression of dysplastic 
lesions of the cervix was shown (Szostek et. al., 2008b, 
Szostek et al., 2011). Some authors showed relatively high 
prevalence of mixed and integrated forms of HPV16 
DNA in cervical epithelial cells obtained from women 
with low grade cervical lesions (Peisaro et al., 2002; Ku-
mala et al., 2006; Huang et al., 2008). In our study, 72.5% 
(29/40) of samples with mixed form of HPV16 and one 
sample with integration of viral genome were detected 
in the LSIL group. In research of Huang and cowork-
ers (2008) mixed form was detected in 83.3% (5/6) of 
samples while in Peisaro and coworkers (2002) – even 
in 93.3% (14 z 15) but in CINI/II group. Furthermore, 
Kumala and coworkers (2006) identified dominant mixed 
form among women with persistent Pap smear abnor-
malities as well as among women who cleared their Pap 
smear abnormalities, 50% and 51.4%, respectively. Our 
findings and the results of previous studies strongly in-
dicate that the integration of HPV16 may occur in the 
early stages of neoplastic transformation of the cervix 
and could be a prognostic factor of cervical cancer.
We found a high incidence of the mixed form of 
HPV16 both in cervical cancer and in LSIL, but we ob-
served that only in samples from cervical cancer with in-
tegrated form of HPV 16 genome two specific variants: 
EUR-350T and EUR-350G, without additional mutations 
dominated. However, it should be noted that the group 
analysed by us consisted of only 23 patients. It was also 
observed that non-synonymous and synonymous muta-
tions were significantly more frequent in the mixed form 
of HPV 16 genome and in LSIL group.
In conclusion, the results of our study showed that, in 
the studied population of women from southern Poland, 
mainly European variants of HPV16 E6 could be found. 
The EUR-350G variant was very common in cervical 
cancer as well as in low grade lesions.
Interestingly, the additional nucleotide changes oc-
curred significantly more often in 350G variants than 
in 350T variants. Thus, we concluded that the presence 
of 350G mutation could affect the number of additional 
nucleotide changes appearing in the studied HPV16 E6 
gene sequence, but this was mostly observed in LSIL.
Our study suggested that 350T and 350G variants 
without additional mutations promoted viral integration 
to the host genome which can lead to cancer develop-
ment. Therefore, it seems that the study of HPV16 E6 
gene polymorphism may have prognostic significance in 
long-term monitoring of women.
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